Bispecific antibodies (bsAbs) are creating a buzz in the world of therapeutic innovation. Known for their ability to bind two different antigens or epitopes simultaneously,

  A prominent CRO, Creative Biolabs, has announced their intention to drive the biopharmaceuticals industry forward and has highlighted the role of recombinant antibody engineering